Technical Analysis for VERV - Verve Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 180 Bearish Setup | Bearish Swing Setup | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | -5.99% | |
| Lower Bollinger Band Walk | Weakness | -5.99% | |
| Wide Bands | Range Expansion | -5.99% | |
| Lower Bollinger Band Touch | Weakness | -5.99% | |
| Oversold Stochastic | Weakness | -5.99% |
| Alert | Time |
|---|---|
| Fell Below Previous Day's Low | about 17 hours ago |
| Fell Below Lower Bollinger Band | about 17 hours ago |
| Down 5% | about 18 hours ago |
| 60 Minute Opening Range Breakdown | about 18 hours ago |
| Possible NR7 | about 18 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/07/2024
Verve Therapeutics, Inc. Description
Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company’s initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease. Verve’s lead product candidate, VERVE-101, is designed to turn off the PCSK9 gene in the liver in order to disrupt blood PCSK9 protein production and thereby reduce blood LDL-C levels, with the goal of reducing a patient’s risk for cardiovascular disease. VERVE-101, currently in IND-enabling studies, is being developed initially for the treatment of patients with heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cardiovascular Disease Lipid Cholesterol Hypercholesterolemia Low Density Lipoprotein Pcsk9
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 19.34 |
| 52 Week Low | 4.305 |
| Average Volume | 1,362,574 |
| 200-Day Moving Average | 7.35 |
| 50-Day Moving Average | 5.39 |
| 20-Day Moving Average | 5.76 |
| 10-Day Moving Average | 5.54 |
| Average True Range | 0.45 |
| RSI (14) | 33.77 |
| ADX | 25.5 |
| +DI | 17.83 |
| -DI | 28.95 |
| Chandelier Exit (Long, 3 ATRs) | 5.46 |
| Chandelier Exit (Short, 3 ATRs) | 5.83 |
| Upper Bollinger Bands | 6.99 |
| Lower Bollinger Band | 4.53 |
| Percent B (%b) | 0.01 |
| BandWidth | 42.67 |
| MACD Line | -0.17 |
| MACD Signal Line | 0.05 |
| MACD Histogram | -0.2164 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.09 | ||||
| Resistance 3 (R3) | 5.13 | 4.98 | 5.00 | ||
| Resistance 2 (R2) | 4.98 | 4.85 | 4.97 | 4.97 | |
| Resistance 1 (R1) | 4.77 | 4.76 | 4.70 | 4.73 | 4.94 |
| Pivot Point | 4.62 | 4.62 | 4.59 | 4.61 | 4.62 |
| Support 1 (S1) | 4.41 | 4.49 | 4.34 | 4.37 | 4.16 |
| Support 2 (S2) | 4.26 | 4.40 | 4.25 | 4.13 | |
| Support 3 (S3) | 4.05 | 4.26 | 4.10 | ||
| Support 4 (S4) | 4.01 |
